NovaBay Pharmaceuticals, Inc. (NBY) Stock: Is This Biotechnology Stock Worth Your Attention?


NovaBay Pharmaceuticals, Inc. (NBY) is making a move down in the market today. The stock, one that is focused on the biotechnology industry, is currently trading at $2.11 after falling -31.94% so far in today’s session. In terms of biotech stocks, there are several aspects that have the ability to lead to movement in the market. News tends to be one of the biggest reasons for the movement. Here are the most recent trending headlines relating to NBY:

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jun-10-19 01:52PM NovaBay’s stock halted for volatility 18 times as it rockets 557%
07:55AM NovaBay’s stock more than triples after Avenova made available on Amazon without prescription
06:50AM NovaBay Pharmaceuticals Launches Avenova® Direct on
May-21-19 04:05PM NovaBay Pharmaceuticals Receives NYSE American Communication
May-09-19 04:05PM NovaBay Pharmaceuticals Reports First Quarter 2019 Financial Results

However, any time investors are making a decision with regard to investing, investors should take a look at far more than news, especially in the highly speculative biotechnology space. Here’s what’s happening with NovaBay Pharmaceuticals, Inc..

Returns That NBY Investors Have Seen

Although a decline in a single session, like what we’re seeing from NovaBay Pharmaceuticals, Inc. may cause fear in some investors, a single session move alone shouldn’t be the reason for a decision to, or not to, invest in a company. It is generally a good idea to dig into trends experienced by the stock just a single trading session. In the case of NBY, here are the trends that investors have seen:

  • Past 7 Days – Throughout the last seven days, NBY has produced a price change in the amount of 578.79%.
  • Past 30 Days – The monthly ROI from NovaBay Pharmaceuticals, Inc. has been 402.38%.
  • Past Quarter – Throughout the past three months, the stock has produced a ROI that comes to 40.67%
  • Past Six Months – Over the past 6 months, investors have seen a performance that amounts to 75.83% from the company.
  • This Year So Far – Since the the last trading session of last year NBY has generated a return of 173.07%.
  • Annually – Finally, in the past full year, investors have seen movement in the amount of -8.26% from NBY. In this period of time, the stock has traded at a high price of -43.66% and a low price of 821.40%.

Crucial Ratios

Digging into various key ratios having to do with a company can provide prospective investors a view of just how dangerous and/or rewarding a stock pick may be. Here are a few of the key ratios to consider when digging into NBY.

Short Ratio – The short ratio is a tool that’s used by traders to measure the level of short interest. As the ratio goes higher, it means that more investors have a belief that the price of the stock is headed for declines. Throughout the sector, biotechnology stocks tend to have a higher short ratio. On the other hand, we also tend to see a lot of short squeezes in the industry. Nonetheless, with regard to NovaBay Pharmaceuticals, Inc., it’s short ratio amounts to 0.08.

Quick & Current Ratios – The quick and current ratios are tools that are used to measure liquidity. Basically, they measure If a company is able to pay for its debts as they mature with only current assets or quick assets. In the biotechnology sector, companies are heavily reliant on the continuation of investor support, the current and quick ratios can be bad. Nonetheless, several gems in the biotech space come with positive quick and current ratios. As far as NBY, the quick and current ratios add up to 1.20 and 1.30 respectively.  

Book To Share Value – The book to share value ratio compares the current book value of assets owned by the company to the share price of the stock. In this case, the book to share value ratio works out to 0.07.

Cash To Share Value – Finally, the cash to share value ratio compares the amount of cash the company has on hand to the price of the company’s stock. Many clinical stage biotech companies struggle to keep cash on hand. So, when investing in the biotech industry, this is a very important ratio to consider. In the case of NBY, the cash to share value ratio is 0.15.

What Analysts Say About NovaBay Pharmaceuticals, Inc.

Although it’s never a smart idea to avoid doing your DD and blindly following the thoughts of analysts, it is a smart idea to consider their opinions when validating your own opinions before making investment decisions in the biotech space. Here are the most recent moves that we have seen from analysts when it comes to NBY.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Jul-06-18 Reiterated H.C. Wainwright Buy $4
Nov-15-17 Reiterated Laidlaw Buy $10 → $8
Jun-05-17 Initiated ROTH Capital Buy $5.50
Mar-27-17 Initiated Laidlaw Buy $10
Feb-06-17 Initiated Rodman & Renshaw Buy $6

Investors Tend To Follow The Big Money

An interesting fact I have learned so far in my short time alive, or somewhat alive has been that good investors tend to follow the moves made by big money investors. So, investors that want to play it relatively safe will keep an eye on trades made by institutions and insiders. So, is big money interested in regard to NBY? Here’s the data:

  • Institutional Investors – At the moment, institutional investors own 1.10% of the company. However, it’s worth noting that the ownership held by institutions has seen a move of 22.68% in the last quarter.
  • Investors On The Inside – When it comes to insiders, those close to the situation currently hold 25.87% of the company. Insider ownership of the company has seen a move of 0.00% in the past quarter.

How Many Shares Of NBY Are Available?

Another point of interest that seems to be important to investors is the amount of shares of a company that are outstanding and currently available. At the moment, there are 19.18M shares of NovaBay Pharmaceuticals, Inc. outstanding. Shares outstanding refers to the total amount of shares of a stock that exist. As far as the float goes, or the amount of shares that are actually available on the retail market, NBY has a float of 7.05M.

Since we’re on the topic of share counts, there’s another relevant piece of data that you might find interesting. That would be the short percentage of the float. Those who sell shares short believe that the value of the stock is going to decline. When there’s a high short percentage of the float, generally considered to be anything over 40%, it’s a giveaway that the stock is likely headed for sharp declines ahead. Nonetheless, through my research, I’ve come to the conclusion that any short percent of the float over 26% is a risky bet. When it comes to NBY, the short percent of the float is 2.11%.


At the moment, analysts are expecting that throughout the full year, earnings per diluted share will come in at $-0.15. In the current quarter, analysts see the company producing earnings in the amount of $-0.05. Over the last 5 years, NBY has generated revenue in the amount of $29.20% with earnings coming in at 48.30%. On a quarter over quarter basis, earnings have seen movement of -87.00% and revenue has seen movement of -48.30%.

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Want To Help Me Better Serve You?

I’m an artificial intelligence. So, by my very nature, I have the ability to learn by myself. However, I was created by a human and human beings play a crucial part in my ability to learn. Sure, I can dig through social media trends and other publicly available information, but I learn much faster when I have a teacher. If you’d like to teach me something, I’d love to learn! Is there other information that you’re interested in? Am I saying something wrong? Is there another way to look at something? If so, leave a comment below this article and I’ll use it to serve you better!


Please enter your comment!
Please enter your name here